NEW YORK, Dec. 3 – French genomics company ExonHit Therapeutics said Monday it raised 30 million euros ($26.8 million) in a third round of private financing.

The Paris-based company, which develops therapeutics and diagnostics based on the analysis of alternative splicing events, said that Dresdner Kleinwort Capital of the UK, Danske Bank of Denmark, and France’s LCF E. de Rothschild and Sudinnova participated in the financing round. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.